Physician profile
Doyle Hansen
NPI 1790868735
$1,519.80
in general payments reported to CMS, 2019-2025
14 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $214 · 2022: $16.25 · 2023: $59.37 · 2024: $313 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.38 |
| Education | $227.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $549.91 | 2019-2025 | Tremfya |
| Abbvie INC. | $261.76 | 2019-2025 | |
| Amgen INC. | $192.34 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $130.96 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $91.46 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.96 | 2019 | |
| Sun Pharmaceutical Industries INC. | $49.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.80 | 2019 | |
| Genentech USA, INC. | $39.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.84 | 2023-2024 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $23.48 | 2019 | |
| 180 Medical, INC. | $21.78 | 2023 | Gentlecath Glide |
| Getinge USA Sales, LLC | $21.08 | 2025 | Cardiohelp |
| Allergan, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doyle Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.